Unique ID issued by UMIN | UMIN000037000 |
---|---|
Receipt number | R000041894 |
Scientific Title | Limited Surgery for T1 or T2 lower rectal Cancer with neoadjuvant chemoradiotherapy |
Date of disclosure of the study information | 2019/06/10 |
Last modified on | 2019/06/07 20:13:29 |
Limited Surgery for T1 or T2 lower rectal Cancer with neoadjuvant chemoradiotherapy
Limited Surgery for T1 or T2 lower rectal Cancer with neoadjuvant chemoradiotherapy
Limited Surgery for T1 or T2 lower rectal Cancer with neoadjuvant chemoradiotherapy
Limited Surgery for T1 or T2 lower rectal Cancer with neoadjuvant chemoradiotherapy
Japan |
Rectal cancer
Surgery in general | Gastrointestinal surgery |
Malignancy
NO
To investigate safety and efficacy of combination therapy of limited Surgery with neoadjuvant chemoradiotherapy for T1 or T2 lower rectal cancer.
Efficacy
Exploratory
Phase II
Pathological complete response rate
Relapse-free survival
Disease-free survival
Overall survival
Local relapse-free survival
Adverse events
Anal sphincter preservation
Anal function
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Xeloda was given orally after breakfast and dinner on Days 1 to 5, 8 to 12, 22 to 26, and 29 to 33.
Radiotherapy was administered in fractions of 1.8 Gy/d, given 5 days per week for 5 weeks. The total dose of radiation was 45 Gy.
20 | years-old | <= |
Not applicable |
Male and Female
1) Main part of the tumor is located in P-Rb.
2) Previously untreated lower rectal cancer with preoperative diagnosis of T1/2 and N0 and M0.
3) Tumor diameter=< 30mm.
4) Well differentiated adenocarcinoma or Moderately differentiated adenocarcinoma.
5) No prior therapy expect the operation.
6) No severe complications
7) Age >= 20 years
8) Performance status (ECOG) of 0-1
9) Capability of oral intake
10) Patients who have satisfied the following the clinical test values within two weeks before the registration.
i. WBC: 3,500-12,000 /mm3
ii. Neutrophile >= 1,500/mm3
iii. Platelet > = 100,000/mm3
iv. Hemoglobin > = 9.0g/dL
v. Total bilirubin =< 2.0 mg/dL
vi. AST =< 100IU/L
vii. ALT =< 100IU/L
viii. Ccr >= 30 ml/min
11) Written informed consent.
1) Active synchronous or metachronous malignancy carcinoma in situ.
2) Non-treated radiotherapy
3) Medical history of severe anaphylaxis or allergia to any drug.
4) Severe diarrhea.
5) Undergoing treatment with Tegafur, Gimeracil, Oteracil Potassium.
6) Undergoing treatment with Warfarin Potassium, Phenytoin, Trifluridine, Tipiracil Hydrochloride.
7) Severe complication.
8) Pregnant or lactating woman at any time during study. Men of the fertility hope.
9) Severe mental disorder.
10) Patients judged inappropriate for the study by their physicians.
20
1st name | Hasegawa |
Middle name | |
Last name | Junichi |
Osaka Rosai Hospital
Department of Surgery
591-8025
1179-3 Nagasonecho, Kita-ku, Sakai 591-8025, Japan
072-252-3561
j-hasegawa@osakah.johas.go.jp
1st name | Sueda |
Middle name | |
Last name | Toshinori |
Osaka Rosai Hospital
Department of Surgery
591-8025
1179-3 Nagasonecho, Kita-ku, Sakai 591-8025, Japan
072-252-3561
tsueda@osakah.johas.go.jp
Osaka Rosai Hospital
None
Self funding
Osaka Rosai Hospital
1179-3 Nagasonecho, Kita-ku, Sakai 591-8025, Japan
072-252-3561
tsueda@osakah.johas.go.jp
NO
2019 | Year | 06 | Month | 10 | Day |
Unpublished
Open public recruiting
2018 | Year | 03 | Month | 05 | Day |
2018 | Year | 03 | Month | 05 | Day |
2018 | Year | 04 | Month | 01 | Day |
2025 | Year | 03 | Month | 31 | Day |
2019 | Year | 06 | Month | 07 | Day |
2019 | Year | 06 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041894